Biomarin Pharmaceuticals
(BMRN)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2014 | 03-2014 | 12-2013 | 09-2013 | 06-2013 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 584,717 | 639,778 | 568,781 | 181,565 | 175,445 |
| Marketable Securities | 251,901 | 247,703 | 215,942 | 198,086 | 225,116 |
| Receivables | 122,282 | 110,462 | 117,822 | 124,745 | 115,063 |
| Inventories | 193,498 | 176,893 | 162,605 | 148,684 | 142,296 |
| Income taxes - deferred | 30,561 | 30,561 | 30,561 | 32,238 | 29,474 |
| Other current assets | 37,268 | 41,013 | 41,707 | 28,161 | 33,526 |
| TOTAL | $1,220,227 | $1,246,410 | $1,137,418 | $713,479 | $720,920 |
| Non-Current Assets | |||||
| PPE Net | 469,862 | 437,066 | 319,316 | 285,664 | 282,002 |
| Investments And Advances | 244,588 | 251,928 | 268,516 | 148,625 | 124,906 |
| Intangibles | 217,303 | 219,655 | 217,405 | 220,049 | 223,409 |
| Other Non-Current Assets | 193,705 | 185,669 | 301,405 | 252,713 | 250,283 |
| TOTAL | $1,125,458 | $1,094,318 | $1,106,642 | $907,051 | $880,600 |
| Total Assets | $2,345,685 | $2,340,728 | $2,244,060 | $1,620,530 | $1,601,520 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 166,720 | 156,038 | 183,271 | 167,633 | 142,241 |
| TOTAL | $166,720 | $156,038 | $183,271 | $167,633 | $142,241 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 716,996 | 724,569 | 719,748 | 139,221 | 163,839 |
| TOTAL | $716,996 | $724,569 | $719,748 | $176,411 | $201,021 |
| Total Liabilities | $883,716 | $880,607 | $903,019 | $344,044 | $343,262 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 147,117 | 145,927 | 143,623 | 142,213 | 140,106 |
| Common Shares | 147 | 146 | 144 | 142 | 140 |
| Retained earnings | -787,418 | -753,916 | -715,801 | -653,811 | -600,791 |
| Other shareholders' equity | -205 | 544 | -2,403 | 4,022 | -5,052 |
| TOTAL | $1,461,969 | $1,460,121 | $1,341,041 | $1,276,486 | $1,258,258 |
| Total Liabilities And Equity | $2,345,685 | $2,340,728 | $2,244,060 | $1,620,530 | $1,601,520 |